Similar articles

• Invasive bladder cancer: organ preservation by radiochemotherapy.

  Rödel C, Grabenbauer GG, Kühn R, Dunst J, Papadopoulos T, Schrott KM, Sauer R. Rödel C, et al. Front Radiat Ther Oncol. 2002;36:118-30. doi: 10.1159/000061334. Front Radiat Ther Oncol. 2002. PMID: 11842742 Review. No abstract available.
• Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours.

  Sengeløv L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, Krarup T, Madsen EL, Meyhoff HH, Mommsen S, Nielsen OS, Pedersen D, Steven K, Sørensen B. Sengeløv L, et al. Acta Oncol. 2002;41(5):447-56. doi: 10.1080/028418602320405041. Acta Oncol. 2002. PMID: 12442921 Clinical Trial.
• [Neoadjuvant chemotherapy: meta-analysis and interpretation of results in bladder cancer].

  Pollera CF. Pollera CF. Suppl Tumori. 2004 Jul-Aug;3(4):S59-61. Suppl Tumori. 2004. PMID: 15206215 Review. Italian. No abstract available.
• Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.

  George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N. George L, et al. Urology. 2004 Sep;64(3):488-93. doi: 10.1016/j.urology.2004.04.088. Urology. 2004. PMID: 15351577 Review.
• Radiochemotherapy for T1G3 bladder cancer.

  Dunst J, Rödel C, Diestelhorst A, Heynemann H, Schrott KM, Sauer R. Dunst J, et al. Front Radiat Ther Oncol. 2002;36:151-8. doi: 10.1159/000061338. Front Radiat Ther Oncol. 2002. PMID: 11842745 Review. No abstract available.